GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (OTCPK:DSKYF) » Definitions » Total Stockholders Equity

Daiichinkyo Co (Daiichinkyo Co) Total Stockholders Equity : $11,268 Mil (As of Mar. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Daiichinkyo Co Total Stockholders Equity?

Daiichinkyo Co's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $11,268 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Daiichinkyo Co's Book Value per Share for the quarter that ended in Mar. 2024 was $5.88. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Daiichinkyo Co's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.06.

Daiichinkyo Co Total Stockholders Equity Historical Data

The historical data trend for Daiichinkyo Co's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daiichinkyo Co Total Stockholders Equity Chart

Daiichinkyo Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12,128.19 11,702.52 11,392.32 10,817.05 11,268.11

Daiichinkyo Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10,817.05 10,822.64 10,781.58 11,017.65 11,268.11

Daiichinkyo Co  (OTCPK:DSKYF) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Daiichinkyo Co's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(11268.114-0)/1917.5
=5.88

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Daiichinkyo Co's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(2.663 + 676.244) / 11268.114
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Daiichinkyo Co Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Daiichinkyo Co's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Daiichinkyo Co (Daiichinkyo Co) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (OTCPK:DSKYF) » Definitions » Total Stockholders Equity
Comparable Companies
TSE:4519 TSE:4503 TSE:4578 TSE:4151 TSE:4528 TSE:4536 TSE:4552 TSE:4882 LLY JNJ MRK ABBV XSWX:ROG LSE:AZN XSWX:NOVN PFE AMGN XPAR:SAN BMY GILD
Traded in Other Exchanges
DSNKY:USA 4568:Japan D4S:Germany
Address
3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, JPN, 103-8426
Website
https://www.daiichisankyo.com
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2021, approximately half of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first U.S approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.